Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

MERCK KGAA

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryAll NewsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Merck : Confirms 2020 Outlook; Prioritizes Lower Debt

share with twitter share with LinkedIn share with facebook
09/16/2020 | 02:45am EDT

By Kim Richters

Merck KGaA on Wednesday backed its outlook for the full year, and said it is currently focusing on organic growth and lowering its debt.

The pharmaceuticals and chemicals company continues to expect slight to moderate organic growth in full-year net sales and Ebitda pre, or earnings before interest, taxes, depreciation and amortization before one-time items.

This equates to sales of 16.9 billion to 17.7 billion euros ($20.02 billion-$20.97 billion) and Ebitda pre of EUR4.45 billion to EUR4.85 billion.

As for its health-care core business, Merck confirmed its target of around EUR2 billion in own pipeline sales by 2022.

For its life-science business, Merck forecasts 6% to 9% average yearly organic sales growth in the medium term.

The company said it is currently prioritizing organic growth and lowering its debt until 2022.

While it won't rule out "large transformative deals" from 2022 onward, Merck said it is likelier to make "a number of smaller to medium-sized acquisitions."

 

Write to Kim Richters at kim.richters@wsj.com

 

share with twitter share with LinkedIn share with facebook
All news about MERCK KGAA
09/21MERCK KGAA : Receives a Sell rating from Goldman Sachs
MD
09/21MERCK : Darmstadt, Germany, Opens State-of-the-art Research Center for Electroni..
PU
09/18MERCK : Agenda
PU
09/18MERCK KGAA : Buy rating from Independant Research
MD
09/18MERCK : BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results Published in The ..
PU
09/17MERCK KGAA : JP Morgan gives a Neutral rating
MD
09/17MERCK KGAA : Credit Suisse gives a Buy rating
MD
09/16MERCK KGAA : Bernstein remains Neutral
MD
09/16MERCK : says it has overcome production shortages in vaccine materials
RE
09/16MERCK KGAA : JP Morgan sticks Neutral
MD
More news
Financials
Sales 2020 17 297 M 20 123 M 20 123 M
Net income 2020 1 704 M 1 983 M 1 983 M
Net Debt 2020 10 875 M 12 652 M 12 652 M
P/E ratio 2020 31,0x
Yield 2020 1,07%
Capitalization 53 912 M 62 638 M 62 722 M
EV / Sales 2020 3,75x
EV / Sales 2021 3,47x
Nbr of Employees 57 523
Free-Float 29,7%
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 122,76 €
Last Close Price 124,00 €
Spread / Highest target 21,0%
Spread / Average Target -1,00%
Spread / Lowest Target -25,8%
EPS Revisions
Managers
NameTitle
Stefan Oschmann Chairman-Executive Board & CEO
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Christian Raabe Independent Member-Supervisory Board
Edeltraud Glänzer Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA17.70%62 638
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD108.35%20 241
KYOWA KIRIN CO., LTD.12.75%14 752
BETTA PHARMACEUTICALS CO., LTD.74.73%6 776
YUHAN CORPORATION30.87%3 294
LUYE PHARMA GROUP LTD.-23.97%1 861